Conclusion
To conclude, Roxadustat as a novel orally administered for the treatment of anemia for CKD. This meta-analysis of the 17 trials with a total of 6673 patients revealed that there were no significant differences in terms of cardiovascular events, renal-related adverse events, the risk of progression to ESKD, or hyperkalemia using Roxadustat for treating anemia in CKD, regardless of whether dialysis was received or not. However, attention must be paid to the occurrence of hypertension in patients with CKD anemia treated with Roxadustat.